KICK OUT PD: Feasibility and quality of life in the pilot karate intervention to change kinematic outcomes in Parkinson's Disease.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 22 11 2019
accepted: 30 07 2020
entrez: 9 9 2020
pubmed: 10 9 2020
medline: 22 10 2020
Statut: epublish

Résumé

Multiple exercise modalities and mindfulness activities are beneficial in Parkinson's Disease (PD). Karate is a martial art that combines aerobic and large-amplitude movements, balance and core training, and mindfulness, suggesting a potential benefit for individuals with PD from multiple perspectives. To evaluate the feasibility of community-based Shotokan karate classes involving physical activity and mindfulness among individuals with mild- to moderate-stage PD, and to explore the effects of karate on objective and patient-reported outcomes. We conducted a 10-week, unblinded trial of twice weekly, PD-specific karate classes. Feasibility was assessed by: dropout rates, adherence via attendance records, adverse effects and falls, and continued participation six months post-intervention. Participants completed pre- and post-intervention assessments of disease-related quality of life (Parkinson's Disease Questionnaire-8, PDQ-8), falls, and post-intervention assessment of change in overall wellbeing (Patient Global Impression of Change, PGIC), with exploratory measures of mobility using the Timed Up and Go (TUG), mood using the Hospital Anxiety and Depression Scale (HADS), and cognition using digit span forward and backward and the Symbol Digit Modalities Test (SDMT). Of 19 enrolled participants, 15 completed the study (79%). Among completers, mean adherence was 87% during the ten weeks of intervention, and 53% maintained karate participation six months later and endorsed sustained improvement, respectively. No adverse effects or change in fall frequency were detected. Among completers, 53% were women, and mean PD duration was 6 years (range 2-20). Quality of life improved to a clinically significant degree (PDQ-8: mean 25.3 (standard deviation (SD) 20.8) versus 19.3 (SD 19.6), p = 0.01, effect size 0.83). On the PGIC, 87% endorsed feeling moderately or considerably better. Mobility did not change significantly (TUG: 9.6 seconds (SD 2.23) versus 9.0 seconds (SD 1.89), p = 0.12, effect size 0.43), nor were there changes in overall physical activity, mood, or cognition (p = 0.35-0.92). In a small, 10-week, unblinded trial of community-based karate classes for individuals with mild and moderate PD, high adherence was noted. Quality of life and wellbeing improved significantly, without changes in exploratory outcomes of mobility or neuropsychological outcomes. The study was underpowered, particularly for the exploratory outcomes. Controlled and longitudinal investigation is warranted to confirm our pilot findings and explore the long-term effects and sustainability of karate in PD. Clinicaltrials.gov: NCT03555695.

Sections du résumé

BACKGROUND
Multiple exercise modalities and mindfulness activities are beneficial in Parkinson's Disease (PD). Karate is a martial art that combines aerobic and large-amplitude movements, balance and core training, and mindfulness, suggesting a potential benefit for individuals with PD from multiple perspectives.
OBJECTIVE
To evaluate the feasibility of community-based Shotokan karate classes involving physical activity and mindfulness among individuals with mild- to moderate-stage PD, and to explore the effects of karate on objective and patient-reported outcomes.
METHODS
We conducted a 10-week, unblinded trial of twice weekly, PD-specific karate classes. Feasibility was assessed by: dropout rates, adherence via attendance records, adverse effects and falls, and continued participation six months post-intervention. Participants completed pre- and post-intervention assessments of disease-related quality of life (Parkinson's Disease Questionnaire-8, PDQ-8), falls, and post-intervention assessment of change in overall wellbeing (Patient Global Impression of Change, PGIC), with exploratory measures of mobility using the Timed Up and Go (TUG), mood using the Hospital Anxiety and Depression Scale (HADS), and cognition using digit span forward and backward and the Symbol Digit Modalities Test (SDMT).
RESULTS
Of 19 enrolled participants, 15 completed the study (79%). Among completers, mean adherence was 87% during the ten weeks of intervention, and 53% maintained karate participation six months later and endorsed sustained improvement, respectively. No adverse effects or change in fall frequency were detected. Among completers, 53% were women, and mean PD duration was 6 years (range 2-20). Quality of life improved to a clinically significant degree (PDQ-8: mean 25.3 (standard deviation (SD) 20.8) versus 19.3 (SD 19.6), p = 0.01, effect size 0.83). On the PGIC, 87% endorsed feeling moderately or considerably better. Mobility did not change significantly (TUG: 9.6 seconds (SD 2.23) versus 9.0 seconds (SD 1.89), p = 0.12, effect size 0.43), nor were there changes in overall physical activity, mood, or cognition (p = 0.35-0.92).
CONCLUSIONS
In a small, 10-week, unblinded trial of community-based karate classes for individuals with mild and moderate PD, high adherence was noted. Quality of life and wellbeing improved significantly, without changes in exploratory outcomes of mobility or neuropsychological outcomes. The study was underpowered, particularly for the exploratory outcomes. Controlled and longitudinal investigation is warranted to confirm our pilot findings and explore the long-term effects and sustainability of karate in PD.
TRIAL REGISTRATION
Clinicaltrials.gov: NCT03555695.

Identifiants

pubmed: 32903267
doi: 10.1371/journal.pone.0237777
pii: PONE-D-19-29980
pmc: PMC7480843
doi:

Banques de données

ClinicalTrials.gov
['NCT03555695']

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0237777

Subventions

Organisme : NIA NIH HHS
ID : P30 AG066512
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Sport Health Sci. 2016 Dec;5(4):484-490
pubmed: 30356535
Res Aging. 2017 Dec;39(10):1118-1144
pubmed: 27688143
Arch Phys Med Rehabil. 1986 Oct;67(10):741-5
pubmed: 3767624
Phys Ther. 2005 Feb;85(2):134-41
pubmed: 15679464
Mov Disord. 2018 Apr;33(4):537-543
pubmed: 29356127
Neurol Clin Pract. 2018 Jun;8(3):214-222
pubmed: 30105161
Neurology. 1992 Jun;42(6):1142-6
pubmed: 1603339
Parkinsonism Relat Disord. 2017 Aug;41:3-13
pubmed: 28602515
Control Clin Trials. 1989 Dec;10(4):407-15
pubmed: 2691207
Complement Ther Med. 2016 Dec;29:121-131
pubmed: 27912936
BMC Public Health. 2017 Jan 25;17(1):115
pubmed: 28122532
Disabil Rehabil. 2020 May;42(9):1270-1274
pubmed: 30621467
Neuroepidemiology. 2017;48(1-2):1-8
pubmed: 28161701
Rev Neurosci. 2013;24(2):139-52
pubmed: 23492553
Front Med (Lausanne). 2016 Aug 17;3:35
pubmed: 27583249
Psychogeriatrics. 2016 Nov;16(6):362-367
pubmed: 26756787
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Res Q Exerc Sport. 2000 Jun;71 Suppl 2:114-20
pubmed: 25680021
J Pain. 2008 Feb;9(2):105-21
pubmed: 18055266
Am J Public Health. 2004 Mar;94(3):361-6
pubmed: 14998794
Aging Clin Exp Res. 2016 Dec;28(6):1179-1186
pubmed: 26661888
Phys Ther. 2011 Jan;91(1):114-21
pubmed: 20947672
Front Neurol. 2019 Dec 04;10:1222
pubmed: 31866923
Asian J Sports Med. 2013 Dec;4(4):263-71
pubmed: 24800001
Mov Disord. 2014 Apr;29(4):539-45
pubmed: 24375468
Parkinsonism Relat Disord. 2007 Feb;13(1):22-8
pubmed: 16931104
Phys Ther. 2007 Oct;87(10):1369-78
pubmed: 17684089
J Parkinsons Dis. 2013 Jan 1;3(3):409-13
pubmed: 23948987
Psychopharmacology (Berl). 2018 Dec;235(12):3443-3450
pubmed: 30315362
Physiother Can. 2011 Winter;63(1):47-57
pubmed: 22210979
Neurology. 2011 Jul 19;77(3):288-94
pubmed: 21768599
Mov Disord. 2004 Sep;19(9):1020-8
pubmed: 15372591
J Gerontol. 1990 Nov;45(6):M192-7
pubmed: 2229941
Front Med (Lausanne). 2017 Dec 19;4:237
pubmed: 29312945
J Parkinsons Dis. 2018;8(s1):S95-S100
pubmed: 30584167
Mov Disord. 2016 Sep;31(9):1342-55
pubmed: 26945525

Auteurs

Jori E Fleisher (JE)

Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, United States of America.

Brianna J Sennott (BJ)

Rush Medical College, Rush University Medical Center, Chicago, Illinois, United States of America.

Erica Myrick (E)

Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, United States of America.

Claire J Niemet (CJ)

Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, United States of America.

Monica Lee (M)

Rush Medical College, Rush University Medical Center, Chicago, Illinois, United States of America.

Courtney M Whitelock (CM)

Rush Medical College, Rush University Medical Center, Chicago, Illinois, United States of America.

Maya Sanghvi (M)

Yale College, Yale University, New Haven, Connecticut, United States of America.

Yuanqing Liu (Y)

Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, United States of America.

Bichun Ouyang (B)

Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, United States of America.

Deborah A Hall (DA)

Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, United States of America.

Cynthia L Comella (CL)

Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, United States of America.

Joshua Chodosh (J)

Department of Medicine, New York University School of Medicine, New York, New York, United States of America.
Medicine Service, VA New York Harbor Healthcare System, New York, New York, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH